Walvax Biotechnology Co., Ltd.
300142
Rank in Stocks
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Share Price
$1.87
Market Cap
$2.98B
Change (1 day)
-3.71%
Change (1 year)
14.73%
Country
CN
Trade Walvax Biotechnology Co., Ltd. (300142)
Category
Healthcare
Number of shares outstanding for Walvax Biotechnology Co., Ltd. (300142)
Number of shares outstanding as of June 2026: 1.60B
According to Walvax Biotechnology Co., Ltd. latest financial reports and stock price the company's current number of shares outstanding is 1.60B. At the end of December 2024 the company had 1.60B shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Walvax Biotechnology Co., Ltd. (300142) from 2007 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 1.60B | 0.00% |
| 2025 | 1.60B | 0.02% |
| 2024 | 1.60B | -0.06% |
| 2023 | 1.60B | -0.07% |
| 2022 | 1.60B | -0.01% |
| 2021 | 1.60B | 3.56% |
| 2020 | 1.55B | 0.52% |
| 2019 | 1.54B | 0.05% |
| 2018 | 1.54B | 0.01% |
| 2017 | 1.54B | 9.09% |
| 2016 | 1.41B | 0.55% |
| 2015 | 1.40B | -2.28% |
| 2014 | 1.43B | -0.18% |
| 2013 | 1.44B | 2.07% |
| 2012 | 1.41B | 0.00% |
| 2011 | 1.41B | 15.17% |
| 2010 | 1.22B | 16.33% |
| 2009 | 1.05B | 66.06% |
| 2008 | 632.71M | 573.74% |
| 2007 | 93.91M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 434.78M | -72.82% |
DE
|
|
| 434.78M | -72.82% |
DE
|
|
| 1.56B | -2.30% |
JP
|
|
| 233.66M | -85.39% |
CH
|
|
| 2.40B | 50.02% |
IN
|
